Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II
Abstract:The effects of the stoichiometric inhibitors tissue factor pathway inhibitor (TFPI), antithrombin-III (AT-III) and heparin cofactor-II (HC-II) on thrombin generation were evaluated in a reaction system composed of coagulation factors VIIa, X, IX, VIII, and V and prothrombin initiated by tissue factor (TF) and phospholipids. Initiation of the reaction in the absence of inhibitors resulted in explosive thrombin generation for factor VIIa⅐TF concentrations varying from 100 to 0.25 pM with the lag time or initiati… Show more
“…Although factor Xa-phospholipid, thrombin, and plasmin are all capable of activating factor V to factor Va, the kinetic evaluation of tissue factor-initiated blood clotting reactions shows that the initial activator of factor V is ␣-thrombin that is initially produced by factor Xa and phospholipid during the initiation phase of the blood coagulation process. 50,52,53,[55][56][57] Although factor Xa-phospholipid is an effective activator of factor V, the concentrations of factor Xa, which exist during the initiation phase of coagulation, are insufficient to explain the activation of factor V that is observed. It is noteworthy that factor Va function is usually measured by its ability to contribute to ␣-thrombin generation.…”
Section: Activationmentioning
confidence: 99%
“…During tissue factor-initiated blood coagulation, thrombin generation can be divided into 2 phases; an initiation phase during which very small amounts of thrombin are produced (ϳ 1%, 5 nM) and clotting is observed; during a subsequent propagation phase 700-to 900-nM thrombin is produced. 50,[55][56][57] The identity of the initial activator of factor V has been a subject of controversy. Although factor Xa-phospholipid, thrombin, and plasmin are all capable of activating factor V to factor Va, the kinetic evaluation of tissue factor-initiated blood clotting reactions shows that the initial activator of factor V is ␣-thrombin that is initially produced by factor Xa and phospholipid during the initiation phase of the blood coagulation process.…”
“…Although factor Xa-phospholipid, thrombin, and plasmin are all capable of activating factor V to factor Va, the kinetic evaluation of tissue factor-initiated blood clotting reactions shows that the initial activator of factor V is ␣-thrombin that is initially produced by factor Xa and phospholipid during the initiation phase of the blood coagulation process. 50,52,53,[55][56][57] Although factor Xa-phospholipid is an effective activator of factor V, the concentrations of factor Xa, which exist during the initiation phase of coagulation, are insufficient to explain the activation of factor V that is observed. It is noteworthy that factor Va function is usually measured by its ability to contribute to ␣-thrombin generation.…”
Section: Activationmentioning
confidence: 99%
“…During tissue factor-initiated blood coagulation, thrombin generation can be divided into 2 phases; an initiation phase during which very small amounts of thrombin are produced (ϳ 1%, 5 nM) and clotting is observed; during a subsequent propagation phase 700-to 900-nM thrombin is produced. 50,[55][56][57] The identity of the initial activator of factor V has been a subject of controversy. Although factor Xa-phospholipid, thrombin, and plasmin are all capable of activating factor V to factor Va, the kinetic evaluation of tissue factor-initiated blood clotting reactions shows that the initial activator of factor V is ␣-thrombin that is initially produced by factor Xa and phospholipid during the initiation phase of the blood coagulation process.…”
“…Factor VIIa-tissue factor activity is regulated by tissue factor pathway inhibitor (TFPI) in a factor Xa-dependent manner (4,5). Ex vivo modeling suggests that initiation of coagulation is a threshold-mediated event related to levels of tissue factor, factor VIIa, and TFPI (6,7). However, significant questions remain regarding the initiation of coagulation, including identification of the factor(s) responsible for generation of circulating factor VIIa and the in vivo expression levels of factor VII, tissue factor, and TFPI activity.…”
It is not known whether the mammalian mechanism of coagulation initiation is conserved in fish. Identification of factor VII is critical in providing evidence for such a mechanism. A cDNA was cloned from a zebrafish (teleost) library that predicted a protein with sequence similarity to human factor VII. Factor VII was shown to be present in zebrafish blood and liver by Western blot analysis and immunohistochemistry. Immunodepletion of factor VII from zebrafish plasma selectively inhibited thromboplastin-triggered thrombin generation. Heterologous expression of zebrafish factor VII demonstrated a secreted protein (50 kDa) that reconstituted thromboplastin-triggered thrombin generation in immunodepleted zebrafish plasma. These results suggest conservation of the extrinsic coagulation pathway between zebrafish and humans and add credence to the zebrafish as a model for mammalian hemostasis. The structure of zebrafish factor VIIa predicted by homology modeling was consistent with the overall three-dimensional structure of human factor VIIa. However, amino acid disparities were found in the epidermal growth factor-2͞serine protease regions that are present in the human tissue factor-factor VIIa contact surface, suggesting a structural basis for the species specificity of this interaction. In addition, zebrafish factor VII demonstrates that the Gla-EGF-EGF-SP domain structure, which is common to coagulation factors VII, IX, X, and protein C, was present before the radiation of the teleosts from the tetrapods. Identification of zebrafish factor VII significantly narrows the evolutionary window for development of the vertebrate coagulation cascade and provides insight into the structural basis for species specificity in the tissue factor-factor VIIa interaction.
“…Effect of Oxidation on Total Thrombin Generation-A prolonged clotting time may indicate only a lengthening of the lag period before feedback loops lead to the explosive generation of thrombin, rather than a decrease in the total amount of thrombin eventually formed (46,47). These two possibilities may not have the same ultimate physiological effect.…”
Section: Effect Of Lipid Oxidation On Apc Anticoagulant Function-mentioning
confidence: 88%
“…Furthermore, small changes in the level or function of natural anticoagulants can have a major effect on potential thrombin generation. Studies of Mann and colleagues (46,47) indicate that a "threshold effect" occurs in coagulation. Thrombin must be generated to a level greater than that threshold for clotting to ensue.…”
Although lipid oxidation products are usually associated with tissue injury, it is now recognized that they can also contribute to cell activation and elicit antiinflammatory lipid mediators. In this study, we report that membrane phospholipid oxidation can modulate the hemostatic balance. Oxidation of natural phospholipids results in an increased ability of the membrane surface to support the function of the natural anticoagulant, activated protein C (APC), without significantly altering the ability to support thrombin generation. Lipid oxidation also potentiated the ability of protein S to enhance APC-mediated factor Va inactivation. Phosphatidylethanolamine, phosphatidylserine, and polyunsaturation of the fatty acids were all required for the oxidation-dependent enhancement of APC function. A subgroup of thrombotic patients with anti-phospholipid antibodies specifically blocked the oxidation-dependent enhancement of APC function. Since leukocytes are recruited and activated at the thrombus or sites of vessel injury, our findings suggest that after the initial thrombus formation, lipid oxidation can remodel the membrane surface resulting in increased anticoagulant function, thereby reducing the thrombogenicity of the thrombus or injured vessel surface. Anti-phospholipid antibodies that block this process would therefore be expected to contribute to thrombus growth and disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.